tbuckley/cabot-search huggingface dataset:
546P Phase I study with expansion cohorts to assess the safety, tolerability, and activity of oral paclitaxel (oPac) + encequidar (E) in combination with pembrolizumab (Pem) in subjects with advanced solid malignancies
Authors: W.W. Ma, P. Singh, R. Manochakian, H. Yoon, A.A. Adjei, Y. Lou, D. Cutler, D. Landers, W-K. Chan, J. Zhi, R. Kwan
Journal: Annals of Oncology (2021)
400P Baseline expression of RAD23B protein in circulating tumor cells correlates with complete pathological response of neoadjuvant chemoradiotherapy for locally advanced rectal cancer
Authors: V.S.E. Silva, E.A. Abdallah, B.D.C. Troncarelli Flores, A. Camila Braun, D. Jesus Ferreira Costa, A.P. Carreta Ruano, V. Alves Gasparini, M.L. Gobo Silva, G. Gomes Mendes, L.C. Lopez Claro, V.F. Calsavara, S. Aguiar, C.A. Mello, L.T. Domingos Chinen
Journal: Annals of Oncology (2021)
Assessment of Clinical and Laboratory Use of the Cutaneous Direct Immunofluorescence Assay
Authors: Julie D. R. Reimann, Sean P. Moynihan, Thomas D. Horn
Journal: JAMA Dermatology (2021)

Dermatologists submit direct immunofluorescence (DIF) biopsies on a daily basis, using an assay detecting immunoreactant deposition with a panel that has traditionally comprised immunoglobulin (Ig) G, IgA, IgM, C3, and fibrin, with or without albumin antibodies.To evaluate and compare the frequency of immunoreactants in DIF biopsies submitted over an 8-year period and assess use by dermatologists based on clinical impression.A quality improvement study was conducted in a community outreach reference laboratory associated with a large academic medical center. Results of 2050 consecutive DIF skin biopsies submitted to the laboratory between April 1, 2012, and June 12, 2020, were analyzed by final pathologic diagnosis and antibody subtype positivity, in comparison with clinical impression. Biopsies in which the submitting physician had not performed the biopsy were excluded.Histopathologic findings and the results of DIF biopsies using the standard 6-antibody panel were evaluated in correlation with the submitted clinical diagnosis to assess immunoreactivity of the assay.Of 2050 DIF biopsies submitted, 367 (17.9%) were positive; IgG, IgA, and C3 alone identified all primary immunobullous disease cases (pemphigoid, pemphigus, linear IgA, and dermatitis herpetiformis), and IgA, C3, and fibrin antibodies alone identified all vasculitis cases. A panel of IgG, IgA, IgM, and fibrin identified all cases of lupus erythematosus. DIF results were positive in less than half of cases of hematoxylin and eosin biopsy-confirmed lupus erythematosus (23 of 47 [49%]). A total of 247 biopsies were submitted for clinical diagnoses not optimally supported on DIF: lichen planus, porphyria, and connective tissue disease.The findings of this study suggest that there is a knowledge gap among dermatologists relating to the opportunity for high-value, cost-conscious use of DIF. The practice of reflexive antibody testing using a 6-antibody panel for all DIF biopsies is likely unnecessary. DIF protocols tailored to the clinical diagnosis may enhance cost-effectiveness without loss of test sensitivity or specificity.
Coronary Artery Bypass Grafting With the Internal Thoracic Artery
Authors: Frank W. Sellke
Journal: JAMA Cardiology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Terms of Use | Privacy Policy | Accessibility Statement 2022 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
829MO A gene signature to predict risk of transformation in patients with follicular lymphoma
Authors: I. Fernandez-Miranda, L. Pedrosa, S. Gómez, J. González-Rincón, B. Espinet, F. Climent, F. de la Cruz, P. Martín-Acosta, L. Colomo, A. Salar, M. García-Cosio, F.R. García-Arroyo, M. Llanos, N. Yánguas, S. Sequero Lopez, S. Mercadal, B. Navarro, M. Mollejo, M. Provencio Pulla, M. Sánchez-Beato
Journal: Annals of Oncology (2021)
Regulatory considerations for animal studies of biomaterial products
Authors: Maobo Cheng, Wenbo Liu, Jiazhen Zhang, Song Zhang, Zhaojun Guo, Lu Liu, Jiaxin Tian, Xiangmei Zhang, Jin Cheng, Yinghui Liu, Gang Deng, Guobiao Gao, Lei Sun
Journal: Bioactive Materials (2021)

Animal studies play a vital role in validating the concept, feasibility, safety, performance and efficacy of biomaterials products during their bench-to-clinic translation. This article aims to share regulatory considerations for animal studies of biomaterial products. After briefly emphasizing the importance of animal studies, issues of animal studies during biomaterial products' translation are discussed. Animal studies with unclear purposes, flawed design and poor reporting quality could significantly reduce the translation efficiency and create regulatory challenges. Regulatory perspectives on the purpose, principle, quality and regulatory science of animal studies are also presented. Animal studies should have clear purposes, follow principles of 3R+DQ (replacement, reduction, refinement, design and quality) and execute under an efficiently operating quality management system. With the advancement of regulatory science, National Medical Products Administration of China has been developing a series of standards and guidance documents on animal studies of medical devices. Case studies of making decisions on whether to conduct animal studies are provided in the end with drug-eluting stents as examples. In summary, animal studies of biomaterial products should pay close attention to the rationale, design and quality in order to achieve their purposes.
923P Nivolumab in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) progressing on/or after a platinum-based therapy: Interim analysis of a prospective French real-world study (ProNiHN)
Authors: C. Le Tourneau, S. Salas, Y. Pointreau, P. Ceruse, E. Babin, M. Chehimi, M. Rotarski, C. Toullec, A. Darut Jouve, A. Najem, P. Combe, D. Burlacu, I. Bourahla, A. Boin, V. Rondeau, C. Even, J. Fayette
Journal: Annals of Oncology (2021)
The Complex Epidemiological Relationship between Flooding Events and Human Outbreaks of Mosquito-Borne Diseases: A Scoping Review
Authors: Jenna E. Coalson, Elizabeth J. Anderson, Ellen M. Santos, Valerie Madera Garcia, James K. Romine, Joy K. Luzingu, Brian Dominguez, Danielle M. Richard, Ashley C. Little, Mary H. Hayden, Kacey C. Ernst
Journal: Environmental Health Perspectives (2021)

Climate change is expected to increase the frequency of flooding events. Although rainfall is highly correlated with mosquito-borne diseases (MBD) in humans, less research focuses on understanding the impact of flooding events on disease incidence. This lack of research presents a significant gap in climate change-driven disease forecasting.We conducted a scoping review to assess the strength of evidence regarding the potential relationship between flooding and MBD and to determine knowledge gaps.PubMed, Embase, and Web of Science were searched through 31 December 2020 and supplemented with review of citations in relevant publications. Studies on rainfall were included only if the operationalization allowed for distinction of unusually heavy rainfall events. Data were abstracted by disease (dengue, malaria, or other) and stratified by post-event timing of disease assessment. Studies that conducted statistical testing were summarized in detail.From 3,008 initial results, we included 131 relevant studies (dengue n=45, malaria n=61, other MBD n=49). Dengue studies indicated short-term (<1 month) decreases and subsequent (1-4 month) increases in incidence. Malaria studies indicated post-event incidence increases, but the results were mixed, and the temporal pattern was less clear. Statistical evidence was limited for other MBD, though findings suggest that human outbreaks of Murray Valley encephalitis, Ross River virus, Barmah Forest virus, Rift Valley fever, and Japanese encephalitis may follow flooding.Flooding is generally associated with increased incidence of MBD, potentially following a brief decrease in incidence for some diseases. Methodological inconsistencies significantly limit direct comparison and generalizability of study results. Regions with established MBD and weather surveillance should be leveraged to conduct multisite research to a) standardize the quantification of relevant flooding, b) study nonlinear relationships between rainfall and disease, c) report outcomes at multiple lag periods, and d) investigate interacting factors that modify the likelihood and severity of outbreaks across different settings. https://doi.org/10.1289/EHP8887.
Zwitterion‐Driven Shape Program of Prodrug Nanoassemblies with High Stability, High Tumor Accumulation, and High Antitumor Activity
Authors: Guanting Li, Bingjun Sun, Shunzhe Zheng, Lu Xu, Wenhui Tao, Dongyang Zhao, Jiang Yu, Shuwen Fu, Xuanbo Zhang, Haotian Zhang, Yinglei Zhai, Cong Luo, Huaiwei Ding, Zhonggui He, Jin Sun
Journal: Advanced Healthcare Materials (2021)

Abstract Prodrug nanoassemblies have emerged as a promising platform for the delivery of anticancer drugs. PEGylation is a “gold standard” to improve colloidal stability and pharmacokinetics of nanomedicines. However, the clinical application of PEG materials is challenged by in vivo oxidative degradation and immunogenicity. Rational design of advanced biomaterials for the surface modification of nanomedicines is the hot spot of research. Here, a zwitterionic sulfobetaine surfactant is constructed as a novel surface modifier to coassemble with 10‐hydroxycamptothecin‐linoleic acid conjugate, with the classical PEGylated material as control. Interestingly, both the type and ratio of surfactants have profound impacts on the molecular mechanisms of the assembly of prodrugs, thereby affecting the pharmaceutical properties. Compared with PEGylated spherical prodrug nanoassemblies, zwitterion‐modified prodrug nanoassemblies have distinct rod shape and superhydrophilic surface, and exhibit potent antitumor activity due to the combination of multiple advantages in terms of colloidal stability, cellular uptake, and pharmacokinetics. The findings illustrate the crucial role of zwitterionic surfactants as the surface modifier in the determination of in vivo fate of the prodrug nanoassemblies, and pave the way for the development of advanced nanomedicines.
1284P Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
Authors: B. Gao, Z. Ma, X. Yu, D. Huang, J. Zhao, D. Day, A.L. Body, Q. Zhou, Q. Chu, H. Pan, J. Cui, C. Chen, X. Xiang, C. Fei, L. Yang, Y-L. Wu
Journal: Annals of Oncology (2021)
1159P Individualized methylation-based dynamic analysis of cell-free DNA in postoperative monitoring of resected lung cancer
Authors: K. Chen, G. Kang, Z. Zhang, A. Lizaso, S. Beck, I. Lyskjær, O. Chervova, B. Li, H. Shen, C. Wang, B. Li, H. Zhao, S. Chuai, F. Yang, N. Kanu, J. Wang
Journal: Annals of Oncology (2021)
Fecal microbiota transplantation and fiber supplementation, better together?
Authors: Nordin M.J. Hanssen, Max Nieuwdorp
Journal: Cell Reports Medicine (2021)

Fecal microbiota transplantation (FMT) is emerging as a tool to study the microbiome and as a potential treatment for several non-infectious diseases. Recently, Mocanu et al. showed that supplementing low fermentable fiber after FMT may improve insulin sensitivity in severely obese individuals.1Mocanu V. Zhang Z. Deehan E.C. Kao D.H. Hotte N. Karmali S. Birch D.W. Samarasinghe K.K. Walter J. Madsen K.L. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial.Nat. Med. 2021; 27: 1272-1279Crossref PubMed Scopus (5) Google Scholar
Corrigendum to ‘detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives’
Authors: Quentin Le Hingrat, Benoit Visseaux, Cédric Laouenan, Sarah Tubiana, Lila Bouadma, Yazdan Yazdanpanah, Xavier Duval, Charles Burdet, Houria Ichou, Florence Damond, Mélanie Bertine, Nabil Benmalek, Christophe Choquet, Jean-François Timsit, Jade Ghosn, Charlotte Charpentier, Diane Descamps, Nadhira Houhou-Fidouh
Journal: Clinical Microbiology and Infection (2021)
Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Authors: Evdoxia Kyriazopoulou, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Georgios Adamis, Konstantinos Tsiakos, Archontoula Fragkou, Aggeliki Rapti, Christina Damoulari, Massimo Fantoni, Ioannis Kalomenidis, Georgios Chrysos, Andrea Angheben, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Maria Tsilika, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Evangelos Kostis, Lorenzo Dagna, Panagiotis Koufargyris, Katerina Dimakou, Spyridon Savvanis, Glykeria Tzatzagou, Maria Chini, Giulio Cavalli, Matteo Bassetti, Konstantina Katrini, Vasileios Kotsis, George Tsoukalas, Carlo Selmi, Ioannis Bliziotis, Michael Samarkos, Michael Doumas, Sofia Ktena, Aikaterini Masgala, Ilias Papanikolaou, Maria Kosmidou, Dimitra-Melia Myrodia, Aikaterini Argyraki, Chiara Simona Cardellino, Katerina Koliakou, Eleni-Ioanna Katsigianni, Vassiliki Rapti, Efthymia Giannitsioti, Antonella Cingolani, Styliani Micha, Karolina Akinosoglou, Orestis Liatsis-Douvitsas, Styliani Symbardi, Nikolaos Gatselis, Maria Mouktaroudi, Giuseppe Ippolito, Eleni Florou, Antigone Kotsaki, Mihai G. Netea, Jesper Eugen-Olsen, Miltiades Kyprianou, Periklis Panagopoulos, George N. Dalekos, Evangelos J. Giamarellos-Bourboulis
Journal: Nature Medicine (2021)
91P Liquid biopsy for detection of minimal residual disease after liver metastasectomy in stage IV colorectal cancer
Authors: M.A. Gouda, M.J. Overman, H.J. Huang, J. Thomas, N.A. Dasari, F. Meric-Bernstam, S. Kopetz, F. Janku
Journal: Annals of Oncology (2021)
Increased somatic mutation burdens in normal human cells due to defective DNA polymerases
Authors: Philip S. Robinson, Tim H. H. Coorens, Claire Palles, Emily Mitchell, Federico Abascal, Sigurgeir Olafsson, Bernard C. H. Lee, Andrew R. J. Lawson, Henry Lee-Six, Luiza Moore, Mathijs A. Sanders, James Hewinson, Lynn Martin, Claudia M. A. Pinna, Sara Galavotti, Raheleh Rahbari, Peter J. Campbell, Iñigo Martincorena, Ian Tomlinson, Michael R. Stratton
Journal: Nature Genetics (2021)

Abstract Mutation accumulation in somatic cells contributes to cancer development and is proposed as a cause of aging. DNA polymerases Pol ε and Pol δ replicate DNA during cell division. However, in some cancers, defective proofreading due to acquired POLE / POLD1 exonuclease domain mutations causes markedly elevated somatic mutation burdens with distinctive mutational signatures. Germline POLE / POLD1 mutations cause familial cancer predisposition. Here, we sequenced normal tissue and tumor DNA from individuals with germline POLE / POLD1 mutations. Increased mutation burdens with characteristic mutational signatures were found in normal adult somatic cell types, during early embryogenesis and in sperm. Thus human physiology can tolerate ubiquitously elevated mutation burdens. Except for increased cancer risk, individuals with germline POLE / POLD1 mutations do not exhibit overt features of premature aging. These results do not support a model in which all features of aging are attributable to widespread cell malfunction directly resulting from somatic mutation burdens accrued during life.
Exercise interventions in Alzheimer’s disease: A systematic review and meta-analysis of randomized controlled trials
Authors: Susana López-Ortiz, Pedro L. Valenzuela, María M. Seisdedos, Javier S. Morales, Tomás Vega, Adrián Castillo-García, Robert Nisticò, Nicola Biagio Mercuri, Simone Lista, Alejandro Lucia, Alejandro Santos-Lozano
Journal: Ageing Research Reviews (2021)
Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
Authors: Amy A Lo, Andrew Wallace, Daniel Oreper, Nicolas Lounsbury, Charles Havnar, Ximo Pechuan-Jorge, Thomas D Wu, Richard Bourgon, Ryan Jones, Katrina Krogh, Guang-Yu Yang, Oliver A Zill
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Individualized neoantigen-specific immunotherapy (iNeST) requires robustly expressed clonal neoantigens for efficacy, but tumor mutational heterogeneity, loss of neoantigen expression, and variable tissue sampling present challenges. It is assumed that clonal neoantigens are preferred targets for immunotherapy, but the distributions of clonal neoantigens are not well characterized across cancer types. Methods We combined multiregion sequencing (MR-seq) analysis of five untreated, synchronously sampled metastatic solid tumors with re-analysis of published MR-seq data from 103 patients in order to characterize their globally clonal neoantigen content and factors that would impact neoantigen targeting. Results Branching evolution in colorectal cancer and renal cell carcinoma led to fewer clonal neoantigens and to clade-specific neoantigens (those shared across a subset of tumor regions but not fully clonal), with the latter not being readily distinguishable in single tumor samples. In colorectal, renal, and bladder cancer, most tumors had few globally clonal neoantigens. Prioritizing mutations with higher purity-adjusted and ploidy-adjusted variant allele frequency enriched for globally clonal neoantigens (those found in all tumor regions), whereas estimated cancer cell fraction derived from clustering-based tools, surprisingly, did not. Neoantigen quality was associated with loss of neoantigen expression in the bladder cancer case, and HLA-allele loss was observed in the renal and non-small cell lung cancer cases. Conclusions We show that tumor type, multilesion sampling, neoantigen expression, and HLA allele retention are important factors for iNeST targeting and patient selection, and may also be important factors to consider in the development of biomarker strategies.
867P A phase I trial of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma
Authors: A. Rosenberg, N. Agrawal, Z. Gooi, E.A. Blair, A.T. Pearson, A. Juloori, L. Portugal, J. Chin, J. Cursio, M. Lingen, D.J. Haraf, E.E. Vokes
Journal: Annals of Oncology (2021)
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
Authors: Bruno Vincenzi, Andrea Napolitano, Marta Fiocco, Olivier Mir, Piotr Rutkowski, Jean-Yves Blay, Peter Reichardt, Heikki Joensuu, Elena Fumagalli, Spyridon Gennatas, Nadia Hindi, Margherita Nannini, Mariella Spalato Ceruso, Antoine Italiano, Giovanni Grignani, Antonella Brunello, Silvia Gasperoni, Tommaso De Pas, Giuseppe Badalamenti, Maria A. Pantaleo, Winan J. van Houdt, Nikki S. IJzerman, Neeltje Steeghs, Hans Gelderblom, Ingrid M.E. Desar, Johanna Falkenhorst, Marianna Silletta, Marta Sbaraglia, Giuseppe Tonini, Javier Martin-Broto, Peter Hohenberger, Axel Le Cesne, Robin L. Jones, Angelo P. Dei Tos, Alessandro Gronchi, Sebastian Bauer, Paolo G. Casali
Journal: Clinical Cancer Research (2021)

The effect of high-dose imatinib (800 mg/day) on survival in the adjuvant treatment of patients with resected KIT exon 9-mutated gastrointestinal stromal tumors (GIST) is not established. Here, the association of dose and other clinicopathologic variables with survival was evaluated in a large multi-institutional European cohort.Data from 185 patients were retrospectively collected in 23 European GIST reference centers. Propensity score matching (PSM) and inverse-probability of treatment weighting (IPTW) were used to account for confounders. Univariate and multivariate unweighted and weighted Cox proportional hazard regression models were estimated for relapse-free survival (RFS), modified-RFS (mRFS) and imatinib failure-free survival (IFFS). Univariate Cox models were estimated for overall survival.Of the 185 patients, 131 (70.8%) received a starting dose of 400 mg/d and the remaining 54 (29.2%) a dose of 800 mg/d. Baseline characteristics were partially unbalanced, suggesting a potential selection bias. PSM and IPTW analyses showed no advantage of imatinib 800 mg/d. In the weighted multivariate Cox models, high-dose imatinib was not associated with the survival outcomes [RFS: hazard ratio (HR), 1.24; 95% confidence interval (CI), 0.79-1.94; mRFS: HR, 1.69; 95% CI, 0.92-3.10; IFFS: HR, 1.35; 95% CI, 0.79-2.28]. The variables consistently associated with worse survival outcomes were high mitotic index and nongastric tumor location.In this retrospective series of patients with KIT exon 9-mutated GIST treated with adjuvant imatinib, a daily dose of 800 mg versus 400 mg did not show better results in terms of survival outcomes. Prospective evaluation of the more appropriate adjuvant treatment in this setting is warranted.
Health secretary must “confront reality,” BMA says after meeting about abuse of GPs
Authors: Elisabeth Mahase
Journal: BMJ (2021)

England’s health secretary must “confront the reality” facing NHS primary care, including the unsustainable workload, poor practice premises, the huge care backlog, and the transfer of work from secondary care, the BMA has said.

The call came after Sajid Javid met the BMA General Practitioners Committee chair, Richard Vautrey, on 23 September to discuss the growing incidence of abuse of GPs and the increased support that primary …
1416P Genomic landscape of late-stage gastric cancer
Authors: Y.Y. Janjigian, M. Cecchini, K. Shitara, P.C. Enzinger, Z.A. Wainberg, D.V. Catenacci, I. Chau, T. Satoh, J. Lee, A. Loboda, J. Kobie, Y. Li, C-S. Shih, R. Cristescu, Z.A. Cao
Journal: Annals of Oncology (2021)
Vigor of reactive postural responses is set from feedback and feedforward processes
Authors: Luis Augusto Teixeira
Journal: Behavioral and Brain Sciences (2021)

Abstract I explore a distinct perspective from that brought in the book by arguing that in postural control our organism selects the vigor of reactive responses guided by an optimization rule considering first the required postural response for balance recovery as indicated by afferent information from a myriad of sensory receptors, and second the history of previous responses to similar perturbations.
Against unitary theories of music evolution
Authors: Peter M. C. Harrison, Madeleine Seale
Journal: Behavioral and Brain Sciences (2021)

Abstract Savage et al. and Mehr et al. provide well-substantiated arguments that the evolution of musicality was shaped by adaptive functions of social bonding and credible signalling. However, they are too quick to dismiss byproduct explanations of music evolution, and to present their theories as complete unitary accounts of the phenomenon.
1791P A phase I pharmacology study of the dual MDMX/MDM2 inhibitor, ALRN 6924, in healthy volunteers
Authors: C. Voors-Pette, W. Aalders, M. Brill, D. Ferrari, A. Annis, U. Steidl, M. Aivado, V. Vukovic
Journal: Annals of Oncology (2021)